Q-omics provides the consensus-scored ANXA6 profile across patient tissues and cancer cell-line models. ANXA6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ANXA6 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, ANXA6 protein abundance shows 33,085 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, and LSCC as cancer lineages where ANXA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANXA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANXA6 survival associations across molecular data types. ANXA6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANXA6 RNA expression–survival associations across cancer types. High ANXA6 expression shows unfavorable associations in BLCA, LUSC and KIRP, but favorable associations in HNSC, PAAD and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for ANXA6 RNA expression.
This table summarizes ANXA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ANXA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANXA6 shows lower tumor expression in BLCA, THCA, LUSC, LUAD and UCEC and higher tumor expression in KIRC. The BLCA box plot shows higher ANXA6 RNA expression in normal versus tumor tissue (log2 FC = −3.264, t-test p < 0.001).
This table shows molecular features associated with ANXA6 in patient tissues and cancer cell lines. In patient samples, ANXA6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANXA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and URINARY_TRACT.
